[ad_1]
1 / 12Tata Motors | Mutued domestic demand and production constraints at JLR weigh on results. Net profit fell 11.2% from last year to ₹3,343 crore. Revenue down 3.8% to ₹1.01 lakh crore. EBITDA down 12% to ₹12,159 crore. EBITDA margin down to 12% from 13.1% last year. JLR profitability impacted by temporary aluminium supply constraint and hold placed on 6,029 vehicles for additional QC checks. JLR expects production and wholesale volumes to pick up strongly in Q2. Hold on to FY25 guidance of revenue of £30 million in revenue and margin of around 8.5%.
2 / 12Asian Paints | Domestic volumes decline by 0.5% compared to estimates of 6-8% growth. Revenue, EBITDA, margin, net profit, all of them below expectations from a CNBC-TV18 poll. Weak consumer sentiment, persistent rains and floods in some parts of the country impacted results. Revenue affected by price cuts taken last year, shift in mix and increased rebates. Operating margins impacted by higher material prices and increased sales expenses. ₹124 Crore impairment of investment value in White Teak Co and ₹56 crore ForEx loss in Ethiopia also impacted profit. Demand conditions remain challenging. Margins to recover due to expected softening in material prices & price increases taken.
3 / 12Ola Electric | Net loss of ₹495 crore from loss of ₹524 crore last year. Revenue up 39% to ₹1,214 crore from ₹973 crore last year. EBITDA loss of ₹349 crore from loss of ₹435 crore last year.
4 / 12LIC | New business premium up 20% to ₹60,043 crore, higher than estimates of ₹58,109 crore. Annual Premium Equivalent (APE) up 26% to ₹16,465 crore compared to estimates of ₹15,885 crore. Retail APE up 31% to ₹11,416 crore, higher than estimates of ₹9,993 crore. VNB up 47% at ₹2,941 crore, higher than estimates of ₹2,313 crore. VNB Margin at 18%, higher than estimates of 14.56%. Net profit down 4% to ₹7,621 crore.
5 / 12Divi’s Laboratories | Revenue up 22.5% to ₹2,338 crore. Net profit up 47% to ₹510 crore. EBITDA up 50% to ₹716 crore. EBITDA margin at 30.6% from 25.1% last year. Double-digit revenue growth, driven by increased demand in custom synthesis and emerging generic. Healthy CS sales and marginal decline in other expenses aided margins. Higher capex of ₹1,600 crore expected in FY25. Kakinada project is progressing, with production expected to start in December 2024.
6 / 12Aarti Industries | Net profit down 43% to ₹52 crore from ₹91 crore last year. Revenue up 12% to ₹1,628 crore from ₹1,454 crore last year. EBITDA down 15.5% year-on-year to ₹197 crore. EBITDA margin at 12.1% from 16% last year.
7 / 12Metropolis | Net profit up 31% to ₹47 crore. Revenue up 11.5% to ₹349 crore. EBITDA up 12.3% to ₹88.5 crore. EBITDA margin at 25.4% from 25.2% last year. Revenue growth led by patient and test volumes. B2C revenue growth of 21% led by growth in Maharashtra, Specialty and TruHealth.
8 / 12Fortis Healthcare | Net profit up 1.6% to ₹176.5 crore. Revenue up 12.3% to ₹1,988.4 crore. EBITDA up 31.7% to ₹435 crore. EBITDA margin at 21.9% from 18.7% last year.
9 / 12JSW Steel | Declared preferred bidder in auction of Banai & Bhalumuda coal block in Mand-Raigarh.
10 / 12Biocon | USFDA classifies Park Site unit in Bengaluru, India as Voluntary Action Initiated (VAI). The facility was inspected between July 15-16, 2024.
11 / 12GR Infra | Declared Lowest Bidder For BSNL’s Bharat Net Phase 3 project worth `867.54 Crore.
12 / 12ITI | Emerges lowest bidder for three packages for Bharat Net Phase-3 project worth ₹4,599 crore.
[ad_2]
Source link